Latest News

  • Startups Taking Multi-Cancer Early Detection Testing to the Next Level

    Diagnostics World | A growing number of promising young companies are developing tests that are particularly good at picking up early cancer, initially for a single type of cancer but with the potential to eventually be extended to multiple cancer types. A handful of these startups will be spotlighted at the upcoming Next Generation Dx Summit .

    Jul 10, 2025

  • Fragmentation Approach to Finding Remnants of Cancer in the Blood

    Diagnostics World | Molecular testing for minimal residual disease (MRD) is increasingly being used to detect cancer recurrence, and to that end many companies are actively developing assays. The tumor-informed approach based on the genetic mutations of patients has been particularly popular and often employs cell-free DNA (cfDNA) and more specifically circulating tumor DNA (ctDNA) analysis.

    Jul 9, 2025

  • Blood Test Detects Cancer with 95% Accuracy Using Microbiome RNA

    Diagnostics World | Researchers at the University of Chicago have published a new approach to cancer detection offering early unprecedented accuracy in identifying both early and late-stage cancers through a simple blood plasma test. The results were published today in a Brief Communication in Nature Biotechnology

    Jul 8, 2025

  • Digital Pathology’s Flywheel Effect: Growing Momentum, Growing Opportunity

    Diagnostics World | For patients who suffer negative health consequences from a delayed diagnosis, new-to-the-scene digital microfluidics (DMF) technology for multifunctional testing can literally save lives. A standout in the field is Baebies (Durham, North Carolina), which has developed a pair of such platforms cleared by the U.S. Food and Drug Administration (FDA) intended for rapid point-of-care testing to aid diagnostic testing in newborns.

    Jul 3, 2025

  • Digital Microfluidics Expanding the Value of Syndromic Testing

    Diagnostics World | For patients who suffer negative health consequences from a delayed diagnosis, new-to-the-scene digital microfluidics (DMF) technology for multifunctional testing can literally save lives. A standout in the field is Baebies (Durham, North Carolina), which has developed a pair of such platforms cleared by the U.S. Food and Drug Administration (FDA) intended for rapid point-of-care testing to aid diagnostic testing in newborns.

    Jul 1, 2025

  • Galatea Bio, Fabric Genomics Combine Pathogenic Variant Analysis with Polygenic Risk Score

    Diagnostics World | Galatea Bio and Fabric Genomics announced a strategic collaboration this week to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases.

    Jun 26, 2025

  • Follow the Money: Neuroplastogens Novel Therapies, Genetic Medicines, More

    Diagnostics World | Elkedonia SAS plans to develop the drug-like small molecule inhibitors of Elk1, a novel intracellular target that plays a pivotal role in reward brain circuits and neuroplasticity; SpliceBio will advance the clinical development of their lead gene therapy candidate, SB-007, for Stargardt disease; and more.

    Jun 25, 2025